Mineralys Therapeutics

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, including hypertension, chronic kidney disease, and obstructive sleep apnea. Its lead product candidate is lorundrostat, an investigational, oral, highly selective aldosterone synthase inhibitor. The company aims to give patients with these cardio-renal conditions a new treatment option.